Mexico The university spin-off UDIBI continues its unstoppable ascension: after being recently recognized by Cofepris, Mexico’s sanitary agency, as an authorized laboratory to assess biotech treatments entering the Mexican market, UDIBI has no started to develop its own, innovative compounds. Sonia Mayra Peréz Tapia, executive director of UDIBI, highlights the ambitious…
Mexico Alexis Serlin, country president of Novartis Mexico and president of CANIFARMA, the industry chamber that brings together multinational and local drug manufacturers, explains how the pharmaceutical industry in Mexico aims to be recognized as a strategic sector by both the Ministries of Health and Economy. He highlights Novartis Mexico’s leadership in…
Mexico Carlos Abelleyra Cordero, CEO Spanish Latin America of Aspen Labs, describes the rapid development of Aspen’s operational capacity throughout the region, in line with the company’s ambition to ultimately establish itself as the commercial partner of choice of big pharma companies in Latin America. He also documents Aspen’s focus on…
Mexico Karel Fucikovsky, general director PFM Latin America at Pierre Fabre, on the strategic focus of the company on operational and commercial excellence in Mexico and Latin America, which both stand as strategic areas for the international growth of the group. He also highlights the main growth opportunities and market challenges the…
Takeda Takeda Mexico’s José Manuel Caamaño discusses Takeda’s impressive growth prospects in Mexico, patient-centricity, the reopening of their cutting-edge manufacturing plant in Naucalpan, and his vision to transform Takeda into one of the most prominent pharmaceutical companies in Mexico, with a strengthened focus on GI and oncology. Christophe Weber, Takeda’s CEO,…
Allergan Dublin-based Allergan has undergone many changes recently, with the acquisition by Actavis, the failed merger with Pfizer, and the divestiture of the generics business to Teva. The company’s SVP and President of Asia Pacific, Rajkumar Narayanan, speaks about the bold new Allergan that has emerged following these events and details their…
Mexico Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart discuss recent developments in the group and the strategic approach behind Bruluart’s impressive growth, helping it to proudly stand as one of the foremost healthcare companies in Mexico. Grupo Bruluart contains well-established pharmaceutical manufacturers, a distribution company, and one of…
Philippines In an exclusive interview, Kamal Abichandani, Deepu Bhatia, Hersh Abichandani, Richard Mayani, the Chairman, Director, General Manager, and Information Systems Manager of Ambica tell their story and reveal their key to success: quality partnerships. As a former engineer without previous experience in the pharmaceutical industry, what were some of the ambitions that…
Singapore Renaud Jonquieres, Vice President Asia-Pacific of bioMérieux Industry, enthusiastically conveys the company’s scope and significance in the Asia-Pacific region, the competitive landscape, as well as the key strategic objective to foster long-term growth. To begin, please provide a brief overview of bioMérieux’s history, including the scope that it encompasses and…
Generics Andreas Bosshard of Mepha-Teva in Switzerland describes Switzerland’s unique generics market, the quality of the Mepha-Teva brand, innovations within generics, and the company’s growth strategy within the Swiss market. It has been five years since the merger of Teva and Mepha in Switzerland, and curiously the brand name Mepha remains in…
Philippines Beaver Tamesis, Managing Director at MSD Philippines, discusses the company’s impressive growth in recent years as well as their expanding portfolio. Additionally, he discusses his work to foster engagement and motivation throughout the MSD affiliate in the country. When we first met you in 2013 you were only a few…
Pharma Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters; reveals how their workforce has increased from a handful of individuals in 2006 to 700 in Switzerland and 2,300 across Europe today; and how Celgene’s continuous R&D investment distinguishes…
See our Cookie Privacy Policy Here
